Scolaris Content Display Scolaris Content Display

Cochrane Database of Systematic Reviews

Certolizumab pegol for induction of remission in Crohn's disease

Esta versión no es la más reciente

ver la versión actual 29 agosto 2019

Información

DOI:
https://doi.org/10.1002/14651858.CD012893Copiar DOI
Base de datos:
  1. Cochrane Database of Systematic Reviews
Versión publicada:
  1. 06 diciembre 2017see what's new
Tipo:
  1. Intervention
Etapa:
  1. Protocol
Grupo Editorial Cochrane:

  1. Grupo Cochrane de Salud digestiva

Copyright:
  1. Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Cifras del artículo

Altmetric:

Citado por:

Citado 0 veces por enlace Crossref Cited-by

Contraer

Autores

  • Hajime Yamazaki

    Correspondencia a: Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan

    [email protected]

  • Ryuhei So

    Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan

  • Katsuyoshi Matsuoka

    Department of Gastroenterology and Hepatology, Tokyo Medical and Dental University, Tokyo, Japan

  • Taku Kobayashi

    Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

  • Shinichiro Shinzaki

    Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Suita, Japan

  • Minoru Matsuura

    Department of Gastroenterology and Hepatology, Kyoto University Hospital, Kyoto, Japan

  • Shinji Okabayashi

    Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo, Japan

  • Yuki Kataoka

    Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan

  • Yasushi Tsujimoto

    Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, Kyoto, Japan

  • Toshi A Furukawa

    Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan

  • Norio Watanabe

    Department of Health Promotion and Human Behavior, Kyoto University Graduate School of Medicine/School of Public Health, Kyoto, Japan

Contributions of authors

Draft the protocol: Hajime Yamazaki, Ryuhei So, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Minoru Matsuura, Shinji Okabayashi, Yuki Kataoka, Yasushi Tsujimoto, Toshi A Furukawa, Norio Watanabe

Develop and run the search strategy: Hajime Yamazaki, Yuki Kataoka, Cochrane IBD Group Information Specialist

Obtain copies of studies: Hajime Yamazaki, Katsuyoshi Matsuoka, Taku Kobayashi, Shinji Okabayashi

Select which studies to include: Hajime Yamazaki, Ryuhei So

Extract data from studies: Hajime Yamazaki, Ryuhei So

Enter data into RevMan: Hajime Yamazaki

Carry out the analysis: Hajime Yamazaki, Yuki Kataoka, Yasushi Tsujimoto, Toshi A Furukawa, Norio Watanabe

Interpret the analysis: Hajime Yamazaki, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Minoru Matsuura, Shinji Okabayashi

Draft the final review: Hajime Yamazaki, Ryuhei So, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Minoru Matsuura, Shinji Okabayashi, Yuki Kataoka, Yasushi Tsujimoto, Toshi A Furukawa, Norio Watanabe

Update the review: Hajime Yamazaki, Ryuhei So, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Minoru Matsuura, Shinji Okabayashi, Yuki Kataoka, Yasushi Tsujimoto, Toshi A Furukawa, Norio Watanabe

Sources of support

Internal sources

  • No sources of support supplied

External sources

  • Japanese Society for Inflammatory Bowel Disease, Japan.

    Research grant

Declarations of interest

Hajime Yamazaki: None known

Ryuhei So: None known

Katsuyoshi Matsuoka received research grants from Eisai, and Abbvie outside of this work; lecture fees from Mitsubishi Tanabe Pharma, Eisai, Abbvie, Kyorin Pharmaceutical, JIMRO, Ajinomoto Pharmaceutical, Janssen, Astellas, Asahi Kasei Medical, Mochida Pharmaceutical, Kissei, Kyowa Hakko Kirin, and Takeda Pharmaceutical.

Taku Kobayashi received recearch grant from Asahi Kasei, Otsuka, Abbvie, Mitsubishi‐Tanabe, JIMRO ,Zaria, EA Pharma and consulting or lecture fees from Asahi Kasei, Abbvie, Kyorin, Mitsubishi‐Tanabe, JIMRO, Zeria, EA Pharma, Mochida and serves as an advisory board member for Janssen, Takeda, Pfizer, and Mochida.

Shinichiro Shinzaki received fees for expert testimony from Kyorin pharmaceutical; grants/grants pending from the Japan Society for the Promotion of Science; payment for lectures from Mitsubishi Tanabe Pharma, Eisai, AbbVie, EA Pharma, Mochida pharmaceutical and Zeria pharmaceutical.

Minoru Matsuura received lecture fees from Mitsubishi‐Tanabe Pharma, Abbvie, EA Pharma Co., Ltd., KYORIN Pharmaceutical, ZERIA Pharmaceutical, AstraZeneka, Daiichi‐Sankyo, Mochida Pharmaceutical, JIMRO, Astellas Pharma Inc. and Nippon Kayaku Co., Ltd.

Shinji Okabayashi: None known

Yuki Kataoka: None known

Yasushi Tsujimoto: None known

Toshi A Furukawa has received lecture fees from Eli Lilly, Janssen, Meiji, MSD, Otsuka, Pfizer and Tanabe‐Mitsubishi, and consultancy fees from Sekisui Chemicals. He has received royalties from Igaku‐Shoin and Nihon Bunka Kagaku‐sha publishers. He has received research support from Mochida and Tanabe‐Mitsubishi.

Norio Watanabe: None known

Acknowledgements

The authors thank John K MacDonald and Tran M Nguyen for their assistance with the development of this protocol.

This project was supported by Japanese Society for Inflammatory Bowel Disease.

Partial funding for the Cochrane IBD Group (April 1, 2016 ‐ March 31, 2018) has been provided by Crohn's and Colitis Canada (CCC).

Version history

Published

Title

Stage

Authors

Version

2019 Aug 29

Certolizumab pegol for induction of remission in Crohn's disease

Review

Hajime Yamazaki, Ryuhei So, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Minoru Matsuura, Shinji Okabayashi, Yuki Kataoka, Yasushi Tsujimoto, Toshi A Furukawa, Norio Watanabe

https://doi.org/10.1002/14651858.CD012893.pub2

2017 Dec 06

Certolizumab pegol for induction of remission in Crohn's disease

Protocol

Hajime Yamazaki, Ryuhei So, Katsuyoshi Matsuoka, Taku Kobayashi, Shinichiro Shinzaki, Minoru Matsuura, Shinji Okabayashi, Yuki Kataoka, Yasushi Tsujimoto, Toshi A Furukawa, Norio Watanabe

https://doi.org/10.1002/14651858.CD012893

PICO

Population
Intervention
Comparison
Outcome

El uso y la enseñanza del modelo PICO están muy extendidos en el ámbito de la atención sanitaria basada en la evidencia para formular preguntas y estrategias de búsqueda y para caracterizar estudios o metanálisis clínicos. PICO son las siglas en inglés de cuatro posibles componentes de una pregunta de investigación: paciente, población o problema; intervención; comparación; desenlace (outcome).

Para saber más sobre el uso del modelo PICO, puede consultar el Manual Cochrane.